Efficacy and safety of administration of Tolvaptan twice daily in hospitalized acute heart failure patients
- Conditions
- acute heart failure
- Registration Number
- JPRN-UMIN000021110
- Lead Sponsor
- Japanese Red Cross Nagoya First Hospital
- Brief Summary
The subjects were assigned to either the once-daily 7.5mg dosing regimen (N=15) or the twice-daily 3.75mg dosing regimen (N=16). The time-course changes in body weight, serum sodium and creatinine levels, systolic blood pressure, daily urine output, and congestion scores were similar between the two groups. In the twice-daily 3.75mg dosing group, the serum sodium levels on days 3 and 4 were significantly (p<0.05) increased compared with those on day 1. The congestion scores significantly (p<0.05) decreased from day 2 to day 7 in both groups compared with those on day 1. However, the difference in the serial change in the congestion scores did not reach statistical significance.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
Subjects with hemodialysis or anuria Subjects with acute coronary syndrome, pregnancy, malignancy, or previously administration of Tolvaptan
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method